These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 16847824)

  • 41. Assessment of futility in clinical trials.
    Snapinn S; Chen MG; Jiang Q; Koutsoukos T
    Pharm Stat; 2006; 5(4):273-81. PubMed ID: 17128426
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Flexible two-stage design with sample size reassessment for survival trials.
    Desseaux K; Porcher R
    Stat Med; 2007 Nov; 26(27):5002-13. PubMed ID: 17577242
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An examination of the efficiency of the sequential parallel design in psychiatric clinical trials.
    Tamura RN; Huang X
    Clin Trials; 2007; 4(4):309-17. PubMed ID: 17848492
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Communicating with the FDA: the "third rail" of a new model for drug development.
    Stanski DR; Orloff JJ
    J Clin Pharmacol; 2008 Feb; 48(2):144-5. PubMed ID: 18199890
    [No Abstract]   [Full Text] [Related]  

  • 45. Repeated confidence intervals for adaptive group sequential trials.
    Mehta CR; Bauer P; Posch M; Brannath W
    Stat Med; 2007 Dec; 26(30):5422-33. PubMed ID: 17918195
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Calculation of sample size for stroke trials assessing functional outcome: comparison of binary and ordinal approaches.
    Optimising Analysis of Stroke Trials Collaboration
    Int J Stroke; 2008 May; 3(2):78-84. PubMed ID: 18705999
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interim futility analysis with intermediate endpoints.
    Goldman B; LeBlanc M; Crowley J
    Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Calculation of sample size in survival trials: the impact of informative noncompliance.
    Jiang Q; Snapinn S; Iglewicz B
    Biometrics; 2004 Sep; 60(3):800-6. PubMed ID: 15339304
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Drug interaction studies: study design, data analysis, and implications for dosing and labeling.
    Huang SM; Temple R; Throckmorton DC; Lesko LJ
    Clin Pharmacol Ther; 2007 Feb; 81(2):298-304. PubMed ID: 17259955
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of proposed FDA criteria for the evaluation of radiolabeled red cell recovery trials.
    Dumont LJ; AuBuchon JP
    Transfusion; 2008 Jun; 48(6):1053-60. PubMed ID: 18298603
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adaptive designs for dose-finding studies based on sigmoid Emax model.
    Dragalin V; Hsuan F; Padmanabhan SK
    J Biopharm Stat; 2007; 17(6):1051-70. PubMed ID: 18027216
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A decision rule for sequential monitoring of clinical trials with a primary and supportive outcome.
    Zhao Y; Grambsch PM; Neaton JD
    Clin Trials; 2007; 4(2):140-53. PubMed ID: 17456513
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Two-stage design of clinical trials involving recurrent events.
    Cook RJ; Bergeron PJ; Boher JM; Liu Y
    Stat Med; 2009 Sep; 28(21):2617-38. PubMed ID: 19579215
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical trial outcome in neuropathic pain: relationship to study characteristics.
    Katz J; Finnerup NB; Dworkin RH
    Neurology; 2008 Jan; 70(4):263-72. PubMed ID: 17914067
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Current issues in non-inferiority trials.
    Fleming TR
    Stat Med; 2008 Feb; 27(3):317-32. PubMed ID: 17340597
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A behavioral Bayes method to determine the sample size of a clinical trial considering efficacy and safety.
    Kikuchi T; Gittins J
    Stat Med; 2009 Aug; 28(18):2293-306. PubMed ID: 19536745
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Statistics in review. Part 2: generalised linear models, time-to-event and time-series analysis, evidence synthesis and clinical trials.
    Moran JL; Solomon PJ
    Crit Care Resusc; 2007 Jun; 9(2):187-97. PubMed ID: 17536991
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Robustness of an odds-ratio test in a stratified group sequential trial with a binary outcome measure.
    Srivastava DK; Rai SN; Pan J
    Biom J; 2007 Jun; 49(3):351-64. PubMed ID: 17623341
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sequential analysis of latent variables using mixed-effect latent variable models: Impact of non-informative and informative missing data.
    Sébille V; Hardouin JB; Mesbah M
    Stat Med; 2007 Nov; 26(27):4889-904. PubMed ID: 17576119
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Conducting a cost-effectiveness trial in oncology: justification and method].
    Lejeune C; Binquet C; Bonnetain F
    Bull Cancer; 2009 May; 96(5):603-7. PubMed ID: 19435689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.